Pan Pantziarka

Program Director for Drug Repurposing @ The Anticancer Fund. Co-founder/Chair The George Pantziarka TP53 Trust (supporting people with Li Fraumeni Syndrome)

[REMEDi4ALL @REMEDi4ALL]

⏳ REMEDi4ALL Academic Bootcamp: applications close tomorrow!

Last chance to apply for the REMEDi4ALL Academic Bootcamp (11–12 March 2026, Cambridge, UK) and get expert support to advance your drug repurposing idea.

🗓️ Deadline: 14 Jan
🔗 https://t.co/nGd389rG20

[REMEDi4ALL @REMEDi4ALL]

🔍New open-access REMEDi4ALL resource for in silico drug repurposing!

Two annotation workflows (KNIME + Python/Neo4j) help extract, harmonise & explore chemical and bioactivity data across >5000 compounds for drug repurposing!

🔗Read the article➡️ https://t.co/gmS7BnfgKP

[Michael Wagner @wagsmd]

Regulatory drug approval and trial design challenges for rare cancers: “Creative approaches emphasizing meaningful clinical impact are needed.” #sarcoma @Dr_R_Kurzrock @VivekSubbiah @myESMO @ASCO @PGrivasMDPhD @DanaFarberNews

https://t.co/qkuX3tA7l5

[Barbara Goodman @goodmanbarb13]

Validating AI driven hypotheses in #ClinicalTrials is critical to provide treatment options for patients with unsolved diseases. Our RFP is open to investigator initiated P1/2A clinical trials testing already approved drugs. Details at https://t.co/IRSS0MvqQn

[Pan Pantziarka @AnticancerOrgUK]

Hot off the press: 'How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancer' - our new paper on tackling drug development in ultra-rare sarcomas.

https://t.co/kxTxWPH1TB

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

This has always been our bottom line.

https://t.co/Wd5AJIwNVq

[SPAGN @sarcomapatients]

Looking forward to #CTOS2025 in Boca Raton with the wonderful @SilviaStacchia as CTOS president. Make sure to stop by the Patient Advocacy Lounge and learn more about #sarcoma #patientadvocacy around the globe!

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a #cancergroundshot trial.

https://t.co/ZnqeplJ7IA

[Dr. Calum Miller @DrCalumMiller]

The euthanasia committee rejected an amendment to ensure people being killed by the state have “met with a palliative care specialist for the purposes of being informed about the medical and care support options."

This is not about choice; it is about cost-cutting. Evil.

[REMEDi4ALL @REMEDi4ALL]

Last call! Register now for our first webinar on Clinical Trials this Friday 21 Feb!

Join us for an introduction on clinical trials with clinical trial experts at ECRIN, joined by Beacon and EURORDIS!

Interested in learning more?

Register now! ➡️ https://t.co/rCOxWi0u8y

[Dr Scott Arthur MP (Edinburgh South West) 🌍🌈🌹 @DrScottArthurMP]

It's fantastic to have @PancreaticCanUK, @BrainTumourOrg and @braintumourrsch all helping to shape my Private Member's Bill on rare cancers.

The vote is on the 14th of March.

Evening News article- https://t.co/nlO4hyWZQW

[REMEDi4ALL @REMEDi4ALL]

🎥Check out our new video on #DrugRepurposing! By building on what we know about a drug's safety & effectiveness, drug repurposing is accelerating the journey from lab to patient.

Watch our video below to learn more, & visit 👉 https://t.co/Bj1Q65vrov

[Krzysztof Potempa @BRAINCURES]

🧵While much of the burgeoning interest in oncological repurposing is related to a few very high profile candidates, such as aspirin or metformin, there is a wide range of non-cancer drugs which have some level of anticancer activity @AnticancerOrgUK
https://t.co/XdfwhC8NZj

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Please do read our letter to editor to @JCO_ASCO with regards to the recent publication of the ARANOTE trial. Until when shall we put up with inferior control arms?
Congratulations @abhenilmittal for raising awareness re this important issue.

https://t.co/UrHNIB20tF

[EMBL-EBI @emblebi]

Osteosarcoma, an aggressive bone cancer, most commonly affects children and young adults.

New research solves the mystery of what drives the genomic rearrangements causing the aggressive development and evolution of osteosarcoma tumours.

https://t.co/vjVofFL63p

[Craig Gedye @DrCraigGedye]

@ANZUPtrials @drcbsteer @Anticancerfund @HMRIAustralia @LUMC_Leiden @CancerAustralia @Prof_IanD @DrL_Krieger

[Anticancer Fund @Anticancerfund]

Proud to have contributed to this article. A must read for policymakers, as this explains why the revision of the EU pharmaceutical legislation is essential for #drugrepurposing, an innovative strategy to find new treatments.
#anticancerfund
@remedi4all @AnticancerOrgUK

[Pan Pantziarka @AnticancerOrgUK]

@WimCeelen @uhasselt @DSI_Uhasselt Congratulations!

[Mariike Kuijjer @mkuijjer]

Are you a Master's student with excellent CV in cancer bioinformatics who is about to defend or recently defended? Would like to do a PhD in the Nordics on cancer network modeling? I have an opportunity with tight deadline. Email your CV and motivation:
https://t.co/H7t0Jkci3U

[David Fajgenbaum, MD @DavidFajgenbaum]

A 100-year-old drug might be a promising treatment for autism spectrum disorder!

A small clinical trial recently revealed that Suramin, a drug originally developed for African sleeping sickness, seems to improve communication skills and social behaviors in individuals with autism.

While the role of medications in treating autism spectrum disorder can be a complex and multifaceted topic we were struck by the evidence suggesting that those who received Suramin experienced significant improvements in their verbal communication skills.

The idea of helping children find their voice is incredibly powerful.

At @EveryCure, we are dedicated to exploring opportunities like Suramin for autism spectrum disorder, as well as other drug-disease matches, to identify the most promising treatments to move forward. #MedTwitter